Welcome, Guest. Please login or register.
February 19, 2020, 12:07:06 pm

Login with username, password and session length

 

Members
Stats
  • Total Posts: 266
  • Total Topics: 132
  • Online Today: 55
  • Online Ever: 518
  • (January 21, 2020, 05:24:49 pm)
Users Online
Users: 0
Guests: 29
Total: 29

Welcome!

Welcome to the Cancer Health Forums, a round-the-clock discussion area for people who have any type of cancer, their friends and family and others with questions about living with cancer. Check in frequently to read what others have to say, post your comments, and hopefully learn more about how you can reach your own health goals.

Privacy Warning: Please realize that these forums are open to all, and are fully searchable via Google and other search engines. If this concerns you, then do not use a username or avatar that are self-identifying in any way. We do not allow the deletion of anything you post in these forums, so think before you post.
  • The information shared in these forums, by moderators and members, is designed to complement, not replace, the relationship between an individual and his/her own physician.
  • All members of these forums are, by default, not considered to be licensed medical providers. If otherwise, users must clearly define themselves as such.
  • Product advertisement (including links); banners; and clinical trial, study or survey participation—is strictly prohibited by forums members unless permission has been secured from the Cancer Health Forum Moderators.
Finished Reading This? You can collapse this or any other box on this page by clicking the symbol in each box.

Author Topic: For Metastatic HER2-Positive Breast Cancer, New Treatments Emerge  (Read 210 times)

Offline Cancer Health Editors

  • Jr. Member
  • **
  • Posts: 51
    • View Profile
Two new treatment options are emerging for women with metastatic breast cancer, following positive results from clinical trials. The trials tested the drugs tucatinib and trastuzumab deruxtecan (Enhertu) in women who had been previously treated for metastatic breast cancer that overproduces the HER2 protein, known as HER2-positive breast cancer.

In one of the trials, called HER2CLIMB, women treated with tucatinib in addition to trastuzumab (Herceptin) and capecitabine lived longer both without their disease progressing and overall than women who received only trastuzumab and capecitabine (Xeloda). The treatment also benefited women in the trial whose cancer had spread to the brain, a particularly challenging group to treat.

Trastuzumab deruxtecan was tested in a smaller trial, called DESTINY-Breast01, and wasn’t compared directly with another treatment. But many women in the study who received the drug saw their tumors shrink and lived for an extended period without their cancer getting worse.

Click here to read more...
https://www.cancerhealth.com/blog/metastatic-her2positive-breast-cancer-new-treatments-emerge

 


© 2020 Smart + Strong. All Rights Reserved.   terms of use and your privacy
Smart + Strong® is a registered trademark of CDM Publishing, LLC.